Molex Acquires Vectura Group to Boost Inhalation Drug Delivery Expertise

Molex, a global leader in electronics, is set to acquire Vectura Group Limited, significantly expanding its capabilities in drug delivery for inhalation therapies. This acquisition, expected to finalize by the end of 2024, will merge Vectura with Phillips Medisize, a Molex subsidiary renowned for designing and manufacturing healthcare products. The consolidation aims to enhance solutions for respitory conditions, benefiting both pharmaceutical clients and patients.

Vectura brings a wealth of inhalation expertise, notably in inhalers, generics, and nebuliser products. Their capabilities span formulation, device development, and regulatory services–a perfect complement to Phillip’s robust manufacturing and engineering strengths. Molex has been strategically enhancing its healthcare portfolio since acquiring Phillips Medisize in 2016. The merger will provide pharmaceutical customers with a comprehensive range of innovative inhalation drug-device combinations. With over 6,000 employees across 29 global locations, Phillips Medisize’s expanded expertise will drive advancements in treating chronic and acute conditions.

The successful integration of Vectura into Molex’s healthcare division marks a significant milestone in the medical device industry. The acquisition will support the creation of innovative products to improve health outcomes for people worldwide.

For the latest updates and in-depth insights into the world of Medical Devices, including mergers, industry trends, and regulatory news, contact Mark Atkinson today!